Attention Deficit and Disruptive Behavior Disorders Clinical Trial
Official title:
Risperidone in the Prevention of Relapse: a Randomized, Double-blind, Placebo-controlled Trial in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders.
The purpose of this study is to assess the efficacy and safety of risperidone as maintenance therapy to prevent symptoms of relapse in children and adolescents with conduct and other disruptive behavior disorders, who initially responded well to treatment.
This is a randomized, double-blind study to compare an oral formulation of risperidone with placebo when taken daily over 24 weeks by children and adolescents with conduct and other disruptive behavior disorders. Patients who do not respond to treatment after an initial 6-week open-label phase, or do not show continued response after 12 weeks, must leave the trial and will not enter into the 24-week double-blind phase. The principal measure of efficacy is the time to symptom relapse. Relapse is assessed by changes in following measures: the Conduct Problem subscale of the Nisonger Child Behavior Rating Form (N-CBRF), a measure of symptoms of conduct and other disruptive behavior disorders and Clinical Global Impression-Severity of Illness (CGI-Severity), and a measure of overall severity of illness. Efficacy assessment also includes Clinical Global Impression-Change (CGI-C), an assessment of improvement, and Visual Analogue Scale for the most troublesome symptom (VAS-MS), which is a scale ranging from not troublesome to extremely troublesome, and Children's Global Assessment Scale (C-GAS), which is an assessment of overall functioning. Safety evaluations include incidence of adverse events, physical examinations, laboratory tests (biochemistry, hematology, and urinalysis), and electrocardiograms (ECGs). The study hypothesis is that daily treatment with an oral formulation of risperidone, compared with placebo, will result in a clinically significant difference in time to relapse, and is well tolerated by children and adolescents with conduct and other disruptive behavior disorders. Oral risperidone solution (1milligram[mg]/milliliter [ml]), daily for 36 weeks. Patients weighing at least 50 kilograms start at 0.5 ml/day and may increase up to.1.5 ml/day. Patients under 50kg start at 0.25ml/day and may increase to 0.75ml/day (maximum). ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00600470 -
Effectiveness of Collaborative Services in Primary Care for Treating Children With Behavior Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT03698240 -
Mindfulness-based Program for Children With Disruptive Behavior Disorder
|
N/A | |
Completed |
NCT02766101 -
Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges
|
N/A | |
Completed |
NCT02897570 -
Metabolic and Neurofunctional Responses to Breakfasts
|
N/A | |
Recruiting |
NCT04946253 -
SKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care
|
N/A | |
Completed |
NCT00402857 -
Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders
|
Phase 3 | |
Completed |
NCT03597789 -
Tantrum Tamers 2.0: The Role of Emotion
|
N/A | |
Recruiting |
NCT01350986 -
Guided Self-Help for Parents of Children With Externalizing Problem Behavior
|
N/A | |
Completed |
NCT00163865 -
A Pilot Study of Boredom in a Community Sample of Adolescents and a Clinical Sample of Adolescents
|
N/A | |
Completed |
NCT02893852 -
Effects of CO-OP Approach on Activity and Participation of Brazilian Children With Developmental Coordination Disorder
|
N/A | |
Terminated |
NCT02094612 -
Effectiveness of the Quotient® ADHD Assessment in a System of Care
|
N/A | |
Completed |
NCT01940978 -
A Study of Combination Therapy in Children With ADHD
|
Phase 4 | |
Completed |
NCT02305134 -
Tipepidine in Children With Attention Deficit/Hyperactivity Disorder (AD/HD): a Double-blind, Placebo-controlled Trial
|
Phase 1/Phase 2 | |
Completed |
NCT03927612 -
Virtual Reality to Improve Social Perspective Taking
|
N/A | |
Completed |
NCT03976570 -
The Effect of Occupational Therapy on Subthreshold Attention Deficit Hyperactivity Disorder
|
N/A | |
Recruiting |
NCT04238403 -
Peer Professionals to Increase Capacity to Treat ADHD
|
N/A | |
Completed |
NCT00218114 -
Divalproex Sodium (Depakote) for Explosive Tempers in Adolescents and Adults
|
Phase 3 | |
Completed |
NCT01919073 -
Efficacy of a Brief Behavioral Intervention to Treat ADHD and Disruptive Behaviors In Preschoolers
|
N/A | |
Completed |
NCT00001233 -
Study of Children at Risk for Disruptive Behavior Disorders
|
N/A | |
Recruiting |
NCT05683756 -
A Sleep Focused Parenting Intervention for Preschool Aged Children at Risk for ADHD
|
N/A |